Cullinan Therapeutics, Inc. (CGEM)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases
I think Cullinan Therapeutics' recent pullback is a compelling price entry ahead of their clinical updates. CGEM has scheduled updates for its autoimmune pipeline for December 2026. The combined CLN-978 results could help corroborate its earlier data. Additionally, if CLN-978 becomes viable for more patients with a manageable safety profile, the potential repeat dosing also seems promising for better efficacy.
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
Cullinan Therapeutics NASDAQ: CGEM outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter.
Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset
Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestones provide a potential funding bridge for advancing CGEM's autoimmune and oncology platforms. CLN-049's accelerated regulatory path in AML and CLN-978's promising early autoimmune data position CGEM for multiple commercialization opportunities.
Cullinan Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 253 | $3,640.66 | $3,450.92 | -$189.74 | -5.21% |
| NA Nizar Araji National Bank Of Canada /FI/ | 23 | $423.66 | $322 | -$101.66 | -24% |
| BG Bart Gancher Intech Investment Management LLC | 12,418 | $94,093.22 | $173,852 | $79,758.78 | 84.77% |
| KM Kristin Mariani Janus Henderson Group PLC | 18,528 | $322,665 | $239,567.04 | -$83,097.96 | -25.75% |
| CD Charlie Durham Sterling Capital Management LLC | 1,219 | $7,228.81 | $16,627.16 | $9,398.35 | 130.01% |
Cullinan Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Robert Driscoll Wedbush | 4,062.09 | $60,159.61 | $54,143.65 | -$6,015.96 | -10% |
Cullinan Therapeutics, Inc. (CGEM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cullinan Therapeutics, Inc. ever had a stock split?
Cullinan Therapeutics, Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Nadim Ahmed CEO | NASDAQ (NGS) Exchange | 230031106 CUSIP |
| US Country | 109 Employees | - Last Dividend | 31 Aug 2009 Last Split | - IPO Date |
Overview
Cullinan Therapeutics, Inc. is a leading biopharmaceutical company based in Cambridge, Massachusetts, dedicated to discovering and developing innovative oncology therapies aimed at improving the lives of cancer patients across the United States. Initially established in 2016 as Cullinan Oncology, Inc., the company underwent a name change to Cullinan Therapeutics, Inc. in April 2024, reflecting its broadened focus on a range of therapeutic solutions beyond oncology. Through its commitment to cutting-edge research and development, Cullinan Therapeutics has positioned itself at the forefront of the biopharmaceutical industry, leveraging strategic partnerships and advanced scientific methodologies to tackle some of the most challenging cancers.
Products and Services
- CLN-619: A monoclonal antibody currently undergoing Phase I clinical trial, CLN-619 is designed for the treatment of solid tumors. This lead program exemplifies Cullinan Therapeutics’ commitment to advancing cancer care through innovative therapeutic solutions.
- CLN-049: A humanized bispecific antibody in Phase I clinical trials, CLN-049 aims to treat acute myeloid leukemia or myelodysplastic syndrome. This product represents the company’s endeavor to address hematologic malignancies with targeted therapies.
- CLN-418: In Phase 1 clinical trial, CLN-418 is a human bispecific immune activator targeted at treating multiple solid tumors. Developed in collaboration with Harbour BioMed US Inc., this therapy showcases Cullinan Therapeutics' focus on harnessing the body’s immune response to combat cancer.
- Zipalertinib: A bioavailable small molecule for patients with non-small cell lung cancer, Zipalertinib is being developed under a co-development agreement with Taiho Pharmaceutical Co., Ltd. It highlights Cullinan Therapeutics’ efforts in targeting specific cancer mutations.
- CLN-617: A fusion protein in development for the treatment of solid tumors, CLN-617 demonstrates the company’s ongoing investment in alternative therapeutic modalities to expand its oncology portfolio.
- CLN-978: Targeting relapsed/refractory B-cell non-Hodgkin lymphoma, CLN-978 is a T cell engaging antibody. This development product further signifies Cullinan Therapeutics’ commitment to exploring novel approaches in cancer immunotherapy.
In addition, Cullinan Therapeutics has forged crucial strategic alliances, including a license and collaboration agreement with Adimab, LLC for antibody discovery and/or optimization. These partnerships enable the enhancement of its R&D capabilities and ensure the development of forward-thinking cancer therapies.
Contact Information
